medicalxpress.com
Discovery of BIRC3 gene variants in Crohn's disease yields a druggable pathway
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to more precise treatments and explain variable responses to anti-TNF drugs.
Clinicians and researchers working on IBD genetics and targeted therapies; patients (including pediatric and adult) with early-onset, familial, or treatment-resistant Crohn's disease who are interested in genetic evaluation; translational researchers and trialists focused on RIPK1 or TNF-pathway drugs.
What To Know
Researchers at SickKids identified variants in the BIRC3 gene in 14 Crohn's patients from 10 families and used cellular, mouse and zebrafish models plus multi-omics to show those variants disrupt the RIPK1/TNF pathway.
The team suggests this pathway could be druggable and relevant beyond rare monogenic cases, potentially helping match patients to targeted therapies. A RIPK1 inhibitor is already in clinical trials elsewhere, which the authors highlight as a possible future treatment option for people whose disease is driven by this pathway.
BIRC3 variants were found to impair a protective function in intestinal cells and activate a RIPK1-related inflammatory route tied to TNF signaling. The researchers combined genetics, RNA sequencing and proteomics and developed animal models to trace how these variants cause gut inflammation.
The study expands the concept of monogenic IBD beyond very early childhood cases: some adults or familial cases may carry single-gene changes that meaningfully affect disease biology and treatment response.
The authors propose using these findings to better predict who may or may not respond to anti-TNF therapies and to explore RIPK1 inhibitors as targeted therapy.
This is promising early translational research, not a new approved treatment; the relevance to broader Crohn's populations and clinical utility will need validation in further studies and clinical trials.
This report summarizes a research study (multi-omics, cellular and animal model work) published in Gastroenterology; it identifies a rare monogenic cause in a small number of families but also suggests broader pathway relevance. Clinical implications depend on replication, broader screening, and results from RIPK1 inhibitor trials.
